☰

Meagan A. Jacoby, Ph.D. - Publications

Affiliations: 
2005 Washington University, Saint Louis, St. Louis, MO 
Area:
Immunology, Medicine and Surgery
Tree Info Similar researchers PubMed Report error

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Shea L, Watkins MP, Wan F, Cashen A, Wagner-Johnston N, Jacoby M, Abboud C, Dipersio J, Hurd D, Jaglowski S, Bartlett NL, Fehniger T. A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32829079 DOI: 10.1016/J.Bbmt.2020.08.017  0.388
2020 Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Nonavinkere Srivatsan S, ... ... Jacoby MA, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discovery. PMID 32826231 DOI: 10.1158/2159-8290.Cd-20-0312  0.339
2019 Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, et al. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. Jama Oncology. PMID 31830234 DOI: 10.1001/Jamaoncol.2019.5140  0.308
2019 Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 721-749. PMID 31200351 DOI: 10.6004/Jnccn.2019.0028  0.302
2019 Garcia-Manero G, Jacoby M, Sallman DA, Han T, Guenot J, Feldman E. A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps7071  0.321
2019 Wei AH, Garcia JS, Borate U, Fong CY, Baer MR, Nolte F, Peterlin P, Jurcic JG, Garcia-Manero G, Hong W, Platzbecker U, Odenike O, Dunbar M, Zhou Y, Harb J, ... ... Jacoby M, et al. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome Blood. 134: 568-568. DOI: 10.1182/Blood-2019-124437  0.302
2018 Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, et al. Mutation Clearance after Transplantation for Myelodysplastic Syndrome. The New England Journal of Medicine. 379: 1028-1041. PMID 30207916 DOI: 10.1056/Nejmoa1804714  0.356
2018 Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Robinson J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Pusic I, Welch JS, Link DC, DiPersio JF, et al. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. Jci Insight. 3. PMID 29515031 DOI: 10.1172/Jci.Insight.98962  0.388
2018 Fong CY, Wei AH, Frattini MG, Jacoby M, Borate U, Gotze KS, Garcia JS, Pollyea DA, Holes L, Zhou Y, Fakouhi KM, Leverson J, Harb JG, Agarwal SK, Attarchi F, et al. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes. Journal of Clinical Oncology. 36: TPS7082-TPS7082. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps7082  0.334
2018 Huselton E, Cashen AF, Jacoby M, Pusic I, Romee R, Uy GL, DiPersio JF, Westervelt P. CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS. Journal of Clinical Oncology. 36: 7027-7027. DOI: 10.1200/Jco.2018.36.15_Suppl.7027  0.315
2018 Jacoby M, Bera R, Fletcher T, Fiala MA, Trinkaus K, DiPersio JF, Stockerl-Goldstein KE, Schroeder MA, Link DC, Vij R. A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Blood. 132: 2146-2146. DOI: 10.1182/Blood-2018-99-115603  0.407
2018 Jacoby M, Spencer DH, Hughes E, Fulton RS, O'Laughlin M, Fronick C, Loken MR, Baty JD, Schroeder MA, Ghobadi A, Uy GL, Vij R, Kahl BS, Cashen AF, Walter MJ, et al. Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance Blood. 132: 5277-5277. DOI: 10.1182/Blood-2018-99-114979  0.389
2017 Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia. Blood. PMID 29203585 DOI: 10.1182/Blood-2017-08-797886  0.37
2017 Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, et al. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Medicine. PMID 29058375 DOI: 10.1002/Cam4.1231  0.356
2017 Kuruvilla J, Savona M, Baz R, Mau-Sorensen M, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma. Blood. PMID 28468797 DOI: 10.1182/Blood-2016-11-750174  0.414
2017 Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, et al. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood. PMID 28082444 DOI: 10.1182/Blood-2016-10-745273  0.326
2017 Uy GL, Rettig MP, Fletcher T, Riedell PA, Stockerl-Goldstein KE, Ghobadi A, Jacoby M, Cashen AF, Romee R, Pusic I, Abboud CN, Schroeder MA, Vij R, Westervelt P, DiPersio JF. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML Blood. 130: 816-816. DOI: 10.1182/Blood.V130.Suppl_1.816.816  0.424
2016 Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, ... ... Jacoby MA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The New England Journal of Medicine. 375: 2023-2036. PMID 27959731 DOI: 10.1056/Nejmoa1605949  0.394
2016 Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reinick T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. PMID 27740633 DOI: 10.1038/Leu.2016.282  0.363
2016 Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, et al. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research. 49: 1-6. PMID 27505705 DOI: 10.1016/J.Leukres.2016.07.010  0.434
2016 Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia & Lymphoma. 1-6. PMID 27122296 DOI: 10.3109/10428194.2016.1173213  0.402
2016 Duncavage EJ, Jacoby MA, Miller C, Chang GS, Shao J, Elliot K, Fronick C, O'Laughlin M, Fulton R, Wilson RK, Graubert TA, Walter MJ. Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression Blood. 128: 959-959. DOI: 10.1182/Blood.V128.22.959.959  0.341
2016 Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Fulton RS, Fronick C, O'Laughlin M, Link DC, DiPersio JF, Westervelt P, Ley TJ, Graubert TA, Walter MJ, et al. Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant Blood. 128: 5506-5506. DOI: 10.1182/Blood.V128.22.5506.5506  0.368
2016 Krysiak K, Jacoby MA, Skidmore ZL, Danos AM, O'Laughlin M, Duncavage EJ, Walter MJ, Griffith M, Griffith OL, Wartman LD. Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis Blood. 128: 4306-4306. DOI: 10.1182/Blood.V128.22.4306.4306  0.348
2015 Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia & Lymphoma. 1-3. PMID 26674111 DOI: 10.1182/Blood.V124.21.5292.5292  0.429
2015 Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26055299 DOI: 10.1016/j.bbmt.2015.05.026  0.337
2015 Welch JS, Petti A, Miller CA, Link DC, Walter MJ, Fronick CC, Fulton RS, Wartman LD, Uy GL, Ghobadi A, Tomasson M, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein K, ... ... Jacoby MA, et al. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients Blood. 126: 689-689. DOI: 10.1182/Blood.V126.23.689.689  0.383
2015 Chen C, Garzon R, Gutierrez M, Jacoby MA, Brown P, Flinn I, Stone RM, Savoie ML, Baz R, Gabrail NY, Wang M, Martin P, Siegel D, Mau-Sørensen M, Andreef M, et al. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Blood. 126: 258-258. DOI: 10.1182/Blood.V126.23.258.258  0.332
2015 Hess BT, Gao F, DiPersio JF, Westervelt P, Vij R, Uy GL, Stockerl-Goldstein K, Abboud CN, Schroeder MA, Pusic I, Ghobadi A, Cashen AF, Fehniger TA, Jacoby MA, Romee R. Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes Blood. 126: 1950-1950. DOI: 10.1182/Blood.V126.23.1950.1950  0.346
2015 Jacoby MA, Abboud CN, Dipersio JF, Cashen AF, Walter MJ, Pizarro RDJ, Uy GL. A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome Blood. 126: 1686-1686. DOI: 10.1182/Blood.V126.23.1686.1686  0.413
2015 Duncavage EJ, O'Brien J, Vij KR, Miller CA, Shao J, Jacoby MA, Fulton RS, Heath S, Janke M, Fronick CC, O'Laughlin M, Wilson RK, Ley TJ, Walter MJ. Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing Blood. 126: 1654-1654. DOI: 10.1182/Blood.V126.23.1654.1654  0.339
2014 Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, Dipersio JF, Cashen AF. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology. 89: E103-8. PMID 24723466 DOI: 10.1002/Ajh.23735  0.404
2014 Jacoby MA, Martin MG, Uy GL, Westervelt P, Dipersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. American Journal of Hematology. 89: 487-92. PMID 24415560 DOI: 10.1002/ajh.23663  0.357
2014 Jacoby MA, De Jesus Pizarro RE, Shao J, Koboldt DC, Fulton RS, Zhou G, Wilson RK, Walter MJ. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia. 28: 1242-51. PMID 24304937 DOI: 10.1038/Leu.2013.368  0.331
2014 Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 46-52. PMID 24120526 DOI: 10.1016/J.Bbmt.2013.10.003  0.37
2014 Fiala MA, Bhamidipati PK, Wang S, Sturgill T, Gao F, Abboud CN, Cashen AF, Jacoby MA, Pusic I, Romee R, Schroeder MA, Uy GL, Vij R, Westervelt P, DiPersio JF, et al. The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT). Journal of Clinical Oncology. 32: 7046-7046. DOI: 10.1200/Jco.2014.32.15_Suppl.7046  0.337
2014 Fiala MA, Park S, Abboud CN, Cashen AF, Jacoby M, Pusic I, Romee R, Schroeder MA, Uy GL, Vij R, Westervelt P, Wildes TM, DiPersio JF, Stockerl-Goldstein KE. Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation Blood. 124: 850-850. DOI: 10.1182/Blood.V124.21.850.850  0.324
2014 Fiala MA, Park S, Abboud CN, Cashen AF, Jacoby M, Pusic I, Romee R, Schroeder MA, Uy GL, Vij R, Westervelt P, Wildes TM, DiPersio JF, Stockerl-Goldstein KE. Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation Blood. 124: 2456-2456. DOI: 10.1182/Blood.V124.21.2456.2456  0.326
2014 Cherian MA, Tibes R, Fletcher T, Fiala MA, Uy GL, Westervelt P, Stockerl-Goldstein KE, Jacoby M, Cashen AF, DiPersio JF, Vij R. A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS Blood. 124: 1931-1931. DOI: 10.1182/Blood.V124.21.1931.1931  0.399
2013 Welch J, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, Dipersio JF, Cashen AF. A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML Blood. 122: 3931-3931. DOI: 10.1182/Blood.V122.21.3931.3931  0.419
2013 Ghobadi A, Fiala MA, Abboud CN, Cashen AF, Eissenberg L, Graubert T, Jacoby MA, Pusic I, Schroeder MA, Stockerl-Goldstein KE, Tomasson MH, Uy GL, Vij R, Walter MJ, DiPersio JF, et al. A Phase I Study Of Azacitidine After Donor Lymphocyte Infusion For Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Blood. 122: 3320-3320. DOI: 10.1182/Blood.V122.21.3320.3320  0.448
2013 Schroeder MA, Grillot M, Reineck T, Jacoby MA, Romee R, Pusic I, Welch J, Uy GL, Cashen AF, Stockerl-Goldstein KE, Vij R, Kulkarni S, Westervelt P, Walter MJ, Dipersio JF. Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial Blood. 122: 2816-2816. DOI: 10.1182/Blood.V122.21.2816.2816  0.379
2013 Bhamidipati P, Fiala MA, Wang S, Sturgill T, Gao F, Abboud CN, Cashen AF, Jacoby M, Pusic I, Romee R, Schroeder MA, Uy GL, Vij R, Westervelt P, DiPersio JF, et al. Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies Blood. 122: 2034-2034. DOI: 10.1182/Blood.V122.21.2034.2034  0.363
2012 Jacoby MA, Walter MJ. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes. Expert Review of Molecular Diagnostics. 12: 253-64. PMID 22468816 DOI: 10.1586/Erm.12.18  0.341
2012 Jacoby MA, de Jesus R, Walter MJ. Trisomy 8 Is Associated with Increased DNA Double Strand Breaks in Primary Myeloblasts Blood. 120: 3492-3492. DOI: 10.1182/Blood.V120.21.3492.3492  0.368
2011 Jacoby MA, de Jesus R, Shao J, Koboldt D, Walter MJ. Dysfunctional DNA Double-Strand Break Repair Is Present in a Subset of Primary t-AML/t-MDS Myeloblasts Blood. 118: 2415-2415. DOI: 10.1182/Blood.V118.21.2415.2415  0.364
2011 Herskowitz JH, Jacoby MA, Speck SH. The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells (Journal of Virology (2005) 79, 4, (2261-2273)) Journal of Virology. 85: 3041. DOI: 10.1128/JVI.00066-11  0.536
2010 Jacoby MA, Jesus Rd, Walter MJ. Dysfunctional Double-Strand DNA Break Repair In Primary t-AML/t-MDS Myeloblasts. Blood. 116: 3366-3366. DOI: 10.1182/Blood.V116.21.3366.3366  0.35
2009 Martin MG, Jacoby M, Shao J, Deych E, Graubert T, Walter MJ. BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia. Blood. 114: 1102-1102. DOI: 10.1182/Blood.V114.22.1102.1102  0.306
2008 Herskowitz JH, Siegel AM, Jacoby MA, Speck SH. Systematic mutagenesis of the murine gammaherpesvirus 68 M2 protein identifies domains important for chronic infection. Journal of Virology. 82: 3295-310. PMID 18234799 DOI: 10.1128/Jvi.02234-07  0.577
2005 Tarakanova VL, Suarez F, Tibbetts SA, Jacoby MA, Weck KE, Hess JL, Speck SH, Virgin HW. Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. Journal of Virology. 79: 14668-79. PMID 16282467 DOI: 10.1128/Jvi.79.23.14668-14679.2005  0.569
2005 Herskowitz JH, Herskowitz J, Jacoby MA, Speck SH. The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells. Journal of Virology. 79: 2261-73. PMID 15681428 DOI: 10.1128/Jvi.79.4.2261-2273.2005  0.61
2003 Tibbetts SA, Loh J, Van Berkel V, McClellan JS, Jacoby MA, Kapadia SB, Speck SH, Virgin HW. Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. Journal of Virology. 77: 7696-701. PMID 12805472 DOI: 10.1128/Jvi.77.13.7696-7701.2003  0.565
2002 Jacoby MA, Virgin HW, Speck SH. Disruption of the M2 gene of murine gammaherpesvirus 68 alters splenic latency following intranasal, but not intraperitoneal, inoculation. Journal of Virology. 76: 1790-801. PMID 11799175 DOI: 10.1128/Jvi.76.4.1790-1801.2002  0.584
1999 van Dyk LF, Hess JL, Katz JD, Jacoby M, Speck SH, Virgin HW IV. The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes. Journal of Virology. 73: 5110-22. PMID 10233974 DOI: 10.1128/Jvi.73.6.5110-5122.1999  0.552
Show low-probability matches.